Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study.

Marc G VervloetIoannis N BoletisAngel L M de FranciscoPhilip A KalraMarkus KettelerPiergiorgio MessaManuela Stauss-GraboAnja DerletSebastian WalpenAmandine PerrinLinda H FicocielloJacques RottembourgChristoph WannerJorge B Cannata-AndíaDenis Fouque

Published in: Clinical kidney journal (2021)

SFOH has a favourable safety and tolerability profile in a real-world setting, consistent with results of the Phase 3 study. Moreover, SFOH improved serum phosphorus control with a low daily pill burden.

Keyphrases

end stage renal disease
chronic kidney disease
peritoneal dialysis
open label
ejection fraction
newly diagnosed
systematic review
prognostic factors
physical activity
clinical trial
double blind
heavy metals
study protocol